Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472081 | 0.89 | MAPT (0.50) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1471217 | 0.89 | THRA (0.52) | THRAMAPTCYP2C9MEN1KMT2A | |
| SCHEMBL6363615 | 0.89 | ALDH1A1 (0.57) | THRAMAPTCYP2C9MEN1KMT2A | |
| SCHEMBL1472133 | 0.88 | THRA (0.53) | THRAMAPTCYP2C9MEN1KMT2A | |
| SCHEMBL5779046 | 0.85 | THRA (0.56) | THRAMAPTCYP2C9MEN1KMT2A | |
| SCHEMBL1472120 | 0.83 | THRA (0.67) | THRAMAPTCYP2C9MEN1KMT2A | |
| SCHEMBL1472253 | 0.80 | THRA (0.52) | THRAMAPTCYP2C9MEN1KMT2A | |
| SCHEMBL1471658 | 0.79 | THRA (0.63) | THRAMAPTCYP2C9MEN1KMT2A | |
| SCHEMBL1471503 | 0.77 | MAPT (0.53) | THRAMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL5798194 | 0.77 | SMN1; SMN2 (0.62) | THRAMAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009871-A1 | Ubiquitin ligase inhibitors | NEDD4, STUB1, UBE3A | THRA 4803/4885MAPT 1796/4885CYP2C9 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.